Aramex PJSC (ARMX.DI) announced the signing of a partnership agreement with New Bridge Pharmaceuticals, a UAE-based regional specialty company that provides one-stop-solutions to pharmaceuticals, biological, genomics and other healthcare companies, where Aramex will provide logistical services for New Bridge in the Middle East, Africa, Canada and the UK. Through the partnership, Aramex will manage the logistics of patient samples across any clinics from the Middle East to the US for clinical testing. Also, Aramex will provide temperature controlled storage and transportation of medication for New Bridge distribution hubs in the UK and Canada to healthcare facilities with the Middle East and Africa, along with the customs clearance, secondary packaging, labelling, vaulting and guarded transport services. In addition to facility hubs based in the UK and Canada, Aramex plans to set-up a third facility hub in the US soon and will continue to handle the storage, transport, and delivery of NewBridge’s pharmaceutical goods. New Bridge pharmaceuticals business model focuses on in-licensing and commercialising FDA and EMA/European approved therapeutics and diagnostics that addresses unmet needs of diseases with high prevalence in the Middle East and Africa. ( Company disclosure)   Aramex (DU): AED3.82 as of 23 August 2016, Rating: Neutral, FV: AED4.45 per share, MCap: USD1,524mn, ARMX UH / ARMX.DU